...
首页> 外文期刊>CNS & neurological disorders drug targets >Changes in cannabinoid receptor subtype 1 activity and interaction with metabotropic glutamate subtype 5 receptors in the periaqueductal gray-rostral ventromedial medulla pathway in a rodent neuropathic pain model
【24h】

Changes in cannabinoid receptor subtype 1 activity and interaction with metabotropic glutamate subtype 5 receptors in the periaqueductal gray-rostral ventromedial medulla pathway in a rodent neuropathic pain model

机译:啮齿动物神经性疼痛模型中导水管周围灰雾腹侧延髓途径中大麻素受体亚型1活性的变化以及与代谢型谷氨酸亚型5受体的相互作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

This study analyzed the effect of intra-ventrolateral periaqueductal grey (VL PAG) cannabinoid receptor (CB) stimulation on pain responses and rostral ventromedial medulla (RVM) neural activity in the chronic constriction injury (CCI) model of neuropathic pain in rats. Interaction between CB 1 and metabotropic glutamate 1 and 5 (mGlu 1/mGlu 5) receptors was also investigated together with the expression of the CB 1 receptor associated Gαi3 and cannabinoid receptor interacting 1a (CRIP 1a) proteins and the endocannabinoid synthesising and hydrolysing enzymes. In rats not subjected to CCI-induced pain, intra-VL PAG (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN 55,212-2) (2-4-8 nmol), a CB receptor agonist, increased the tail flick latency and changed the ongoing activity of RVM OFF and the tail flick-related activity of the ON and OFF cells, accordingly. These effects were prevented by SR141716A and MPEP, selective CB 1 and mGlu 5 receptor antagonists, respectively, though not by CPCCOEt, a selective mGlu 1 receptor antagonist. A higher dose up to 16 nmol of WIN 55,212-2 was necessary to increase tail flick latency and change ON and OFF cell activity in CCI rats. Consistently, CCI rats showed a decrease in the expression of CB 1 receptors, NAPE-PLD, Gαi3 and CRIP 1a proteins;the expression of diacylglycerol lipase A (DAGLA) was increased while fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL) did not change. As in control rats, MPEP and SR141716A also blocked WIN 55,212-2- induced effects in CCI rats. These data demonstrate a down regulation of the endocannabinoid system and a functional interaction between mGlu 5 and CB 1 receptors for cannabinoid-mediated effect in the PAG-RVM pain circuitry in neuropathic pain inflicted rats.
机译:这项研究分析了在大鼠神经性疼痛的慢性收缩性损伤(CCI)模型中,腹侧导水管内灰色(VL PAG)大麻素受体(CB)刺激对疼痛反应和延髓腹侧延髓(RVM)神经活动的影响。还研究了CB 1与代谢型谷氨酸1和5(mGlu 1 / mGlu 5)受体之间的相互作用,以及与CB 1受体相关的Gαi3和大麻素受体相互作用1a(CRIP 1a)蛋白的表达以及内源性大麻素合成和水解酶的作用。在未遭受CCI诱导疼痛的大鼠中,VL-PAG(R)-(+)-[2,3-二氢-5-甲基-3-(4-吗啉基甲基)吡咯并[1,2,3-de] -1,4-苯并恶嗪-6-基] -1-萘甲磺酸甲磺酸酯(WIN 55,212-2)(2-4-8 nmol),CB受体激动剂,增加了甩尾潜伏期并改变了RVM的持续活性相应地,ON和OFF细胞的尾部轻拂相关活动。选择性的CB 1和mGlu 5受体拮抗剂SR141716A和MPEP分别阻止了这些作用,选择性的mGlu 1受体拮抗剂CPCCOEt则未阻止这些作用。为了增加尾部甩动潜伏期并改变CCI大鼠的ON和OFF细胞活性,最高剂量达到16 nmol的WIN 55,212-2更高。一致地,CCI大鼠的CB 1受体,NAPE-PLD,Gαi3和CRIP 1a蛋白的表达降低;二酰基甘油脂酶A(DAGLA)的表达增加,而脂肪酸酰胺水解酶(FAAH)和单酰基甘油脂酶(MGL)的表达增加没有改变。与对照大鼠一样,MPEP和SR141716A也阻断了CCI大鼠中WIN 55,212-2-诱导的作用。这些数据证明了内源性大麻素系统的下调以及mGlu 5和CB 1受体之间的功能性相互作用对神经性疼痛大鼠中PAG-RVM疼痛回路中的大麻素介导的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号